SCHEMBL3369810

SCHEMBL3369810

NCc1cccc(-c2ccc3nc(C(=O)Nc4ccccc4)cn3c2)c1

nearest known ligand 0.59

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.59
NR4A2 P43354 2/20 0.59
EGLN1 Q9GZT9 11/20 0.56
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
DGAT1 O75907 1/20 0.50
CFD P00746 1/20 0.49
KCNH2 Q12809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3368804 0.90 NR4A2 (0.60) CYP2C9NR4A2EGLN1NPC1RAB9A
SCHEMBL3366348 0.85 CYP2C9 (0.73) CYP2C9NR4A2EGLN1NPC1RAB9A
SCHEMBL3367633 0.84 CYP2C9 (0.64) CYP2C9NR4A2EGLN1NPC1RAB9A
SCHEMBL3367808 0.84 EGLN1 (0.72) CYP2C9NR4A2EGLN1NPC1RAB9A
SCHEMBL3366318 0.84 NR4A2 (0.63) CYP2C9NR4A2EGLN1NPC1RAB9A
SCHEMBL3369748 0.84 EGLN1 (0.71) CYP2C9NR4A2EGLN1NPC1RAB9A
SCHEMBL3368278 0.84 NR4A2 (0.65) CYP2C9NR4A2EGLN1NPC1RAB9A
SCHEMBL3368544 0.82 NR4A2 (0.60) CYP2C9NR4A2EGLN1NPC1RAB9A
SCHEMBL3370912 0.82 NR4A2 (0.63) CYP2C9NR4A2EGLN1NPC1RAB9A
SCHEMBL3367641 0.81 EGLN1 (0.62) CYP2C9NR4A2EGLN1DGAT1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404848-B2 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics SANOFI (FR) 2013-03-26 US claimed
EP-2041133-B1 DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2010-10-13 EP claimed
US-7704989-B2 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2010-04-27 US claimed
US-20090149441-A1 DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2009-06-11 US claimed
US-8404848-B2 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics SANOFI (FR) 2013-03-26 US disclosed
EP-2041133-B1 DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2010-10-13 EP disclosed
US-7704989-B2 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2010-04-27 US disclosed
US-20090149441-A1 DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2009-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149441-A1 DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS NR4A2, NR4A3, NCOR1 CYP2C9 2834/4885NR4A2 1/4885EGLN1 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.